AD17002

BIOLOGICAL4 trials

Sponsors

Advagene Biopharma Co. Ltd.

Conditions

Allergic RhinitisCOVID-19Eosinophilic Asthma

Phase 1

Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

CompletedNCT04088721

Advagene Biopharma Co. Ltd.Allergic Rhinitis

Start: 2019-03-26End: 2020-12-11Updated: 2025-09-16

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

CompletedNCT05069610

Advagene Biopharma Co. Ltd.COVID-19

Start: 2022-03-21End: 2023-12-18Updated: 2023-12-22

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

CompletedNCT05985694

Advagene Biopharma Co. Ltd.Eosinophilic Asthma

Start: 2023-11-27End: 2025-04-27Updated: 2025-09-10

Phase 2

A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

Not yet recruitingNCT07250594

Advagene Biopharma Co. Ltd.Eosinophilic Asthma

Start: 2025-12-31End: 2026-12-31Target: 126Updated: 2025-11-26